US2010331252A1PendingUtilityA1

Myostatin inhibitor enhancement of musculoskeletal repair

28
Individually held — no corporate assignee on recordPriority: Jun 25, 2009Filed: Jun 25, 2010Published: Dec 30, 2010
Est. expiryJun 25, 2029(~2.9 yrs left)· nominal 20-yr term from priority
Inventors:Mark Hamrick
A61K 47/20A61K 47/42A61K 9/0092A61K 9/5153A61K 9/06A61K 9/0019A61K 38/179A61P 19/04A61K 38/18A61P 19/00
28
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The methods and compositions of this invention provide a means of regenerating injured musculoskeletal tissue by inhibition of myostatin function. The invention provides methods of treating a nonunion fracture in an individual comprising delivering to the fracture via a delivery system comprising biodegradable hydrogel, a pharmacological amount of myostatin propeptide effective to inhibit myostatin function. The invention also teaches compositions useful for the treatment of non-union fracture in an individual, said compositions comprising a pharmacological amount of myostatin propeptide effective to inhibit myostatin function; and a delivery system for delivering said myostatin propeptide to said fracture, wherein the delivery system comprises a biodegradable hydrogel or biodegradable nanobeads.

Claims

exact text as granted — not AI-modified
1 . A method of regenerating injured musculoskeletal tissue, comprising:
 contacting the injured tissue with a myostatin inhibitor, wherein said contact results in musculoskeletal tissue regeneration by inhibition of myostatin function.   
     
     
         2 . The method of  claim 1 , wherein the myostatin inhibitor is myostatin propeptide. 
     
     
         3 . The method of  claim 1 , wherein the myostatin inhibitor is a soluble myostatin receptor. 
     
     
         4 . The method of  claim 1 , wherein said myostatin inhibitor is delivered to said injured musculoskeletal tissue via a biodegradable delivery system. 
     
     
         5 . The method of  claim 4 , wherein said delivery system is a biodegradable hydrogel. 
     
     
         6 . The method of  claim 5 , wherein said biodegradable hydrogel comprises hyaluronan-gelatin and heparin. 
     
     
         7 . The method of  claim 4 , wherein said delivery system is biodegradable nanobeads. 
     
     
         8 . The method of  claim 1 , wherein said injured musculoskeletal tissue is a fractured bone. 
     
     
         9 . A method of treating a fracture in an individual comprising:
 administering a pharmacological amount of a myostatin inhibitor effective to inhibit myostatin function, thereby treating the fracture.   
     
     
         10 . The method of  claim 9 , wherein the myostatin inhibitor is myostatin propeptide. 
     
     
         11 . The method of  claim 9 , wherein the myostatin inhibitor is myostatin receptor. 
     
     
         12 . The method of  claim 9 , wherein said myostatin inhibitor is delivered to the fractured bone via a biodegradable delivery system. 
     
     
         13 . The method of  claim 12 , wherein said delivery system is a biodegradable hydrogel comprising hyaluronan-gelatin and heparin. 
     
     
         14 . The method of  claim 12 , wherein said delivery system is biodegradable nanobeads. 
     
     
         15 . The method of  claim 9 , wherein said fracture is a nonunion fracture. 
     
     
         16 . A method of treating a fracture in an individual comprising:
 contacting said fracture with a biodegradable delivery vehicle containing a pharmacological amount of a myostatin inhibitor effective to inhibit myostatin function, thereby treating the fracture.   
     
     
         17 . The method of  claim 16 , wherein the myostatin inhibitor is myostatin propeptide. 
     
     
         18 . The method of  claim 16 , wherein said delivery system is a biodegradable hydrogel comprising hyaluronan-gelatin and heparin. 
     
     
         19 . The method of  claim 16 , wherein said delivery system is a biodegradable nanobead. 
     
     
         20 . The method of  claim 16 , wherein said fracture is a nonunion fracture. 
     
     
         21 . A method of treating a nonunion fracture in an individual comprising:
 contacting said fracture with a biodegradable delivery vehicle containing a pharmacological amount of a myostatin propeptide effective to inhibit myostatin function, thereby treating the fracture.   
     
     
         22 . The method of  claim 21 , wherein the biodegradable delivery vehicle comprises biodegradable nanobeads. 
     
     
         23 . A biodegradable composition containing a pharmacological amount of myostatin propeptide. 
     
     
         24 . The composition of  claim 23 , wherein said composition is a hydrogel. 
     
     
         25 . The composition of  claim 24 , wherein said hydrogel comprises hyaluronan-gelatin and heparin. 
     
     
         26 . The composition of  claim 23 , wherein said composition is a nanobead.

Join the waitlist — get patent alerts

Track US2010331252A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.